Lipocine Inc. (NASDAQ:LPCN) traded up 2.5% on Friday . The company traded as high as $3.74 and last traded at $3.62, with a volume of 76,759 shares. The stock had previously closed at $3.53.

Separately, Canaccord Genuity restated a “buy” rating and set a $6.00 target price on shares of Lipocine in a research report on Wednesday, August 10th.

The firm has a 50 day moving average price of $3.67 and a 200-day moving average price of $7.78. The stock’s market capitalization is $66.09 million.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.05. Analysts forecast that Lipocine Inc. will post ($1.31) EPS for the current year.

An institutional investor recently raised its position in Lipocine stock. Dimensional Fund Advisors LP increased its position in Lipocine Inc. (NASDAQ:LPCN) by 73.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 271,272 shares of the specialty pharmaceutical company’s stock after buying an additional 114,448 shares during the period. Dimensional Fund Advisors LP owned approximately 1.49% of Lipocine worth $3,508,000 at the end of the most recent reporting period.

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.